Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.62 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.46 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4816542 | 0.98 | MAPK14 (0.62) | MAPK14HSPB1PTPN1KCNK3KCNK9 | |
| SCHEMBL4702778 | 0.96 | MAPK14 (0.66) | MAPK14HSPB1PTPN1KCNK3KCNK9 | |
| SCHEMBL4701504 | 0.91 | MAPK14 (0.69) | MAPK14HSPB1KCNK3KCNK9KMT2A | |
| SCHEMBL4819651 | 0.80 | MAPK14 (0.74) | MAPK14HSPB1 | |
| SCHEMBL5380271 | 0.79 | MAPK14 (0.64) | MAPK14HSPB1KCNK3KCNK9RAB9A | |
| SCHEMBL4700704 | 0.78 | MAPK14 (0.64) | MAPK14HSPB1PTPN1 | |
| SCHEMBL4822705 | 0.78 | MAPK14 (0.72) | MAPK14HSPB1 | |
| SCHEMBL4811975 | 0.77 | MAPK14 (0.71) | MAPK14HSPB1 | |
| SCHEMBL6236279 | 0.77 | KCNK3 (0.54) | MAPK14HSPB1KCNK3KCNK9KMT2A | |
| SCHEMBL5122976 | 0.77 | MAPK14 (0.62) | MAPK14HSPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432289-B2 | 5-Acylamino-1,1′-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2008-10-07 | — | — | US | disclosed |
| US-7151118-B2 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-12-19 | — | — | US | disclosed |
| US-20050020540-A1 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-01-27 | — | — | US | disclosed |
| US-20040242868-A1 | 5-acylamino-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242868-A1 | 5-acylamino-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | MAPK1, MAP3K1, MAPK7 | MAPK14 17/4885HSPB1 1461/4885PTPN1 746/4885 |
| US-20050020540-A1 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | MAPK1, MAPKAPK2, MAP3K1 | MAPK14 32/4885HSPB1 690/4885PTPN1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.